FindTrial
Sign In

AKR1B10 molecular mechanism of lenvatinib resistance in hepatocellular carcinoma cells and its clinical value

AKR1B10 molecular mechanism of lenvatinib resistance in hepatocellular carcinoma cells and its clinical value

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094901
Enrollment
Unknown
Registered
2024-12-30
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocarcinoma

Interventions

Observation group:None

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Liver cancer patients treated with lenvatinib in our hospital will be collected, and about 100 people will be enrolled

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
AKR1B10;—

Countries

China

Contacts

Public ContactLu Zheng

Xuzhou Central Hospital

xsdzhenglu@163.com+86 516 80812386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026